Yahoo Finance

Vaso Occlusive Crisis Market revenue to surpass USD 20 Billion by 2036, says Research Nester

New York, Dec. 06, 2023 (GLOBE NEWSWIRE) -- The global vaso occlusive crisis market size is projected to expand at 8% CAGR between 2024 and 2036. The market is expected to garner a revenue of USD 20 ...
Monthly Prescribing Reference

ASH: Prasugrel Doesn’t Cut Vaso-Occlusive Crisis in Sickle Cell

(HealthDay News) — The rate of vaso-occlusive crisis events is not significantly lower for children and adolescents with sickle cell anemia receiving prasugrel versus placebo, according to a study ...
FierceBiotech

GlycoMimetics and Pfizer Enter into Licensing Agreement for Drug Candidate Currently in Development to Treat Patients Expe

GAITHERSBURG, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. announced today that it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. (NYSE: PFE) for the GlycoMimetics ...
The American Journal of Managed Care

Phase 3 Data Show Exa-Cel Prevents Vaso-Occlusive Crises for At Least 1 Year in SCD

Data from the study showed that exa-cel prevented vaso-occlusive crises in all but 1 of the 30 evaluable patients for at least 12 months. Exagamglogene autotemcel (exa-cel; Casgevy) prevented ...
Nasdaq

New Supportive Efficacy Data for GlycoMimetics’ Rivipansel in Sickle Cell Acute Vaso-Occlusive Crisis Presented at 62nd ASH Annual Meeting and Exposition

Open label study demonstrated statistically significant effects of early treatment with rivipansel on time to discharge and time to discontinuation of intravenous opioids Benefit of early intervention ...
Nature

Peripartum acute liver failure from a vaso-occlusive crisis in a patient with sickle cell trait

The patient was diagnosed with acute liver failure, acute renal failure and metabolic acidosis. In the setting of elevated liver function tests, hypoglycemia, coagulopathy and hyperammonemia, AFLP was ...

Exa-cel gene therapy may off effective cure for beta-thalassemia and sickle cell disease in children younger than 12

Preliminary results from two trials of the gene therapy exagamglogene autotemcel (exa-cel) suggest the therapy offers an ...
Business Insider

GBT Expands Sickle Cell Disease Pipeline with Worldwide Licensing Agreement for Inclacumab for the Treatment of Vaso-occlusive Crisis

SOUTH SAN FRANCISCO, Calif., Aug. 23, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) announced today that it has entered into an exclusive worldwide licensing agreement ...
The Manhattan Mercury

U.S. ERs Are Failing Sickle Cell Patients In Pain, Study Says

Only 1 in 3 patients in an ER for sickle cell crisis receive opioid painkillers within the first hour as treatment guidelines ...
FierceBiotech

GlycoMimetics and Pfizer Enter into Licensing Agreement for Drug Candidate Currently in Development to Treat Patients

GlycoMimetics and Pfizer Enter into Licensing Agreement for Drug Candidate Currently in Development to Treat Patients Experiencing Vaso-occlusive Crisis Associated with Sickle Cell Disease ...
Business Wire

GlycoMimetics and Pfizer Enter into Licensing Agreement for Drug Candidate Currently in Development to Treat Patients Experiencing Vaso-occlusive Crisis Associated with Sickle ...

GAITHERSBURG, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. announced today that it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. (NYSE: PFE) for the GlycoMimetics ...